Epigral Limited (formerly known as Meghmani Finechem Limited) has shared its financial outlook and capital expenditure plans for the fiscal year 2026, indicating a positive trajectory for the company's performance.

Financial Projections

Epigral expects the second half of FY26 to outperform the first half, signaling confidence in its business strategy and market conditions. The company has projected its net debt to be approximately Rs 600.00 crores for the fiscal year.

Capital Expenditure Plans

The chemical manufacturer has outlined an ambitious capital expenditure plan of Rs 450.00 crores for FY26. Notably, the company has already utilized Rs 120.00 crores in the first quarter, demonstrating swift implementation of its expansion strategy.

Q1 FY26 Results and Investor Communication

As per the recent LODR (Listing Obligations and Disclosure Requirements) filings, Epigral has been proactive in its investor communications:

• The company published its unaudited financial results for the first quarter ended June 30, 2025, in major newspapers on August 3rd and 4th, 2025.
• An audio recording of the conference call discussing Q1 FY26 results has been made available on the company's website.
• Epigral is scheduled to have a one-on-one virtual meeting with New Mark Capital on August 6, 2025, to discuss its latest earnings and corporate presentations.

Transparency and Compliance

Epigral continues to maintain transparency with its stakeholders by promptly sharing financial results, hosting investor calls, and adhering to regulatory requirements. The company has assured that no unpublished price-sensitive information will be shared during its upcoming investor meeting.

As Epigral navigates through FY26, investors and market watchers will be keen to observe how the company's strategic investments and projected second-half performance materialize in the face of evolving market dynamics.

Epigral , a leading integrated chemical manufacturer in India, has announced plans to raise up to ₹4 billion through the issuance of bonds. This strategic move comes on the heels of the company's robust financial performance in the first quarter.

Bond Issuance Details

The company's Board of Directors has approved a proposal to raise funds up to ₹400 crore (₹4 billion) through the issuance of non-convertible debentures, bonds, and/or other debt securities. This fundraising initiative will be executed through permissible modes within the company's borrowing limits, potentially in multiple tranches or series over a period of time, subject to necessary regulatory and other approvals.

Q1 Financial Highlights

Epigral's decision to raise funds through bonds is backed by a strong financial performance in Q1:

• Revenue from operations stood at ₹606.54 crore
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) reached ₹163 crore, maintaining a healthy margin of 27%
• Profit After Tax (PAT) surged to ₹160.41 crore, including a one-time tax benefit

Key Financial Metrics

Strategic Initiatives

Maulik Patel, Chairman and Managing Director of Epigral, commented on the company's performance and outlook: "We maintained our EBITDA margin of 27% on account of sustaining efficiency level and better product mix. We expect H2 to be stronger compared to H1."

The company is also progressing with its capacity expansion plans:

• CPVC Resin capacity will be increased to 1,50,000 TPA
• Epichlorohydrin capacity will be expanded to 1,00,000 TPA
• A new 19.80 MW Wind Solar Hybrid Power Plant is under development

Market Position

Epigral continues to strengthen its position in the specialty chemical business. The revenue contribution from Derivatives and Specialty business stood at 50% in Q1, with expectations of further increase.

The proposed bond issuance aligns with Epigral's strategy of sustainable growth and value creation for stakeholders. As the company moves forward with its expansion plans and focus on high-value products, this fundraising initiative is expected to provide the necessary capital to support its growth trajectory in the competitive chemical manufacturing sector.

Investors and market watchers will be keenly observing how Epigral utilizes these funds to drive its strategic initiatives and maintain its strong market position in the coming quarters.